LONDON, March 4 /PRNewswire/ -- Alveolus, Inc. announced the successful implantation of the first AERO(TM) tracheobronchial stent technology system in the United Kingdom, a significant milestone for the company as it begins commercializing the product throughout Europe.

"This first implant in the UK is a significant achievement for Alveolus," said Eric Mangiardi, President and Chief Executive Officer of Alveolus. "We are hopeful that the AERO(TM) system will become the preferred treatment option for physicians throughout the UK and Europe for both malignant and benign obstructive pulmonary diseases."

"The advantages of the AERO stent were immediately apparent when first used -- it was deployed with ease and with great accuracy under direct bronchoscopic vision and without the need for a general anesthetic. In my opinion, it has the potential to improve the management of malignant airway obstruction and now merits in depth clinical evaluation," said Jeremy George, M.D., Middlesex Hospital, London.

  The AERO(TM) stent system received CE Mark approval in October 2004.

  About Alveolus

Headquartered in Charlotte, NC, Alveolus is a leading developer of non- vascular interventional stent technology. Alveolus' advanced stenting technology enhances the quality of life for patients who suffer from pulmonary or gastrointestinal obstruction. The Alveolus product ideation process, guided by world leading interventionalists, allows for rapid prototyping and development of products to address the specific requirements for each area of the body. Products are created by physicians, for physicians, with an end goal of enhancing the quality of life and reducing the long term medical costs for patients and their families.

This press release is provided in good-faith by Chiltern Magazine Services Ltd ("CMS") as a service to users. Whilst every care is taken in sourcing and preparing material included here, any error or incorrect content cannot form the basis for any legal action against the site-owner. Users are advised to check the accuracy of any statements before relying upon them. Likewise, any forward-looking statements made by the author of the press release should be treated as such.

For full details, please email keithw@cmsinfo.com